Literature DB >> 24599386

[Localization of parathyroid adenomas with C11-methionine PET-CT].

T Weber1, M Luster.   

Abstract

BACKGROUND AND OBJECTIVES: In primary hyperparathyroidism (pHPT) preoperative localization of parathyroid adenomas enables focussed unilateral parathyroidectomy. Ultrasound and sestamibi scintigraphy are the recommended standard procedures for primary diagnostics of pHPT and C-11 methionine positron emission tomography computed tomography (Met-PET/CT) is the latest technique for localization of hyperfunctioning parathyroid glands.
METHODS: This review presents the results of Met-PET/CT on the basis of a selective literature search using the keywords "primary hyperparathyroidism and methionine", "primary hyperparathyroidism and PET", "parathyroid adenomas and methionine" and "parathyroid adenomas and PET".
RESULTS: Localization of single gland adenomas can be achieved with Met-PET/CT in 79-91 % of cases. The advantages of this procedure are a high sensitivity even in operations for recurrencies or concomitant thyroid nodules and an accurate detection even with atypical localizations. In multiglandular disease a localization of more than one hyperfunctioning gland remains difficult. Potential limitations of the method include the restricted availability and the relatively high costs of Met-PET/CT.
CONCLUSIONS: Using Met-PET/CT hyperfunctioning parathyroid glands can be exactly localized in most patients with pHPT. Indications for this procedure are mostly when preoperative standard tests are negative and in parathyroid surgery for recurrencies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24599386     DOI: 10.1007/s00104-013-2695-5

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  29 in total

1.  Tc-99m-MIBI-negative parathyroid adenoma in primary hyperparathyroidism detected by C-11-methionine PET/CT after previous thyroid surgery.

Authors:  Matthias C Schmidt; Deniz Kahraman; Bernd Neumaier; Monika Ortmann; Dirk Stippel
Journal:  Clin Nucl Med       Date:  2011-12       Impact factor: 7.794

2.  Intrathoracic metastatic spread of parathyroid carcinoma.

Authors:  C Maier-Funk; T Weber; G Lang; S Hügl; S N Reske; M Luster
Journal:  Nuklearmedizin       Date:  2010       Impact factor: 1.379

3.  Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors?

Authors:  Jeffrey L Anderson; Ryan C Vanwoerkom; Benjamin D Horne; Tami L Bair; Heidi T May; Donald L Lappé; Joseph B Muhlestein
Journal:  Am Heart J       Date:  2011-08       Impact factor: 4.749

4.  Localization of hyperfunctioning parathyroid glands by selective venous sampling in reoperation for primary or secondary hyperparathyroidism.

Authors:  Margot A Reidel; Tobias Schilling; Stefanie Graf; Ulf Hinz; Peter Nawroth; Markus W Büchler; Theresia Weber
Journal:  Surgery       Date:  2006-10-19       Impact factor: 3.982

5.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop.

Authors:  John P Bilezikian; Aliya A Khan; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958

6.  Positional statement of the European Society of Endocrine Surgeons (ESES) on modern techniques in pHPT surgery.

Authors:  Anders O J Bergenfelz; Per Hellman; Barney Harrison; Antonio Sitges-Serra; Henning Dralle
Journal:  Langenbecks Arch Surg       Date:  2009-07-03       Impact factor: 3.445

7.  Patient-based surgical outcome tool demonstrating alleviation of symptoms following parathyroidectomy in patients with primary hyperparathyroidism.

Authors:  Janice L Pasieka; Louise L Parsons; Michael J Demeure; Stuart Wilson; Peter Malycha; Jean Jones; Beth Krzywda
Journal:  World J Surg       Date:  2002-05-21       Impact factor: 3.352

8.  Accurate pre-operative localization of pathological parathyroid glands using 11C-methionine PET/CT.

Authors:  Bich-Ngoc-Thanh Tang; Rodrigo Moreno-Reyes; Didier Blocklet; Bernard Corvilain; Matteo Cappello; Isabelle Delpierre; France Devuyst; Gaetan Van Simaeys; Serge Goldman
Journal:  Contrast Media Mol Imaging       Date:  2008 Jul-Aug       Impact factor: 3.161

9.  Planar scintigraphy with 123I/99mTc-sestamibi, 99mTc-sestamibi SPECT/CT, 11C-methionine PET/CT, or selective venous sampling before reoperation of primary hyperparathyroidism?

Authors:  Camilla Schalin-Jäntti; Eeva Ryhänen; Ilkka Heiskanen; Marko Seppänen; Johanna Arola; Jukka Schildt; Mika Väisänen; Lassi Nelimarkka; Irina Lisinen; Ville Aalto; Pirjo Nuutila; Matti J Välimäki
Journal:  J Nucl Med       Date:  2013-04-03       Impact factor: 10.057

10.  Comparison of radiation exposure and cost between dynamic computed tomography and sestamibi scintigraphy for preoperative localization of parathyroid lesions.

Authors:  Catherine A Madorin; Randall Owen; Brian Coakley; Hannah Lowe; Kee-Hyun Nam; Kaare Weber; Leon Kushnir; Jose Rios; Eric Genden; Puneet S Pawha; William B Inabnet
Journal:  JAMA Surg       Date:  2013-06       Impact factor: 14.766

View more
  3 in total

1.  Preoperative ¹¹C-methionine PET/CT enables focused parathyroidectomy in MIBI-SPECT negative parathyroid adenoma.

Authors:  Christina Lenschow; Peter Gassmann; Christian Wenning; Norbert Senninger; Mario Colombo-Benkmann
Journal:  World J Surg       Date:  2015-07       Impact factor: 3.352

2.  The use of computed tomography as a first-line imaging modality in patients with primary hyperparathyroidism.

Authors:  Mechteld C de Jong; K Jamal; S Morley; T Beale; T Chung; S Jawad; S Hurel; H Simpson; U Srirangalingam; S E Baldeweg; V Rozalén García; S Otero; M Shawky; T E Abdel-Aziz; T R Kurzawinski
Journal:  Hormones (Athens)       Date:  2020-05-13       Impact factor: 2.885

3.  Evaluation of diagnostic efficacy for localization of parathyroid adenoma in patients with primary hyperparathyroidism undergoing repeat surgery.

Authors:  Anne Hendricks; Christina Lenschow; Matthias Kroiss; Andreas Buck; Ralph Kickuth; Christoph-Thomas Germer; Nicolas Schlegel
Journal:  Langenbecks Arch Surg       Date:  2021-05-16       Impact factor: 3.445

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.